-
Mashup Score: 2
Irene Ghobrial:Good morning, good afternoon everyone. We are here live in Myeloma 2022 for the first time seeing people in person, discussing amazing data on multiple myeloma. And I’m joined here today by an amazing panel to talk mainly about single-cell sequencing and how can we understand drug resistance, response to therapy, mechanisms in general of both immune and cancer cells, and how can we…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Hermann Einsele:Hello, everybody. My name is Hermann Einsele. I am based in Würzburg in Germany, and it’s my great pleasure to report from the Myeloma 2022 in Scottsdale. And it’s a great pleasure for me for the discussion to have two real experts with me on T-cell engaging therapies in myeloma, Professor Nina Shah and Professor Tom Martin from California. And the topic of our discussion today…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | At #Myeloma22, leading experts @H_Einsele, @TomBmt133 & @ninashah33 got together to discuss the latest in T-cell engager therapies. Watch here: 🎥: https://t.co/59AN6VQmsq #MMsm #Myeloma #HemOnc #ImmunoOnc https://t.co/dsW3BjYvmv
-
-
Mashup Score: 1Myeloma Sessions: Day 1 highlights from Myeloma 2022 | VJHemOnc - 2 year(s) ago
Keith Stewart:We’re here at Myeloma 2022 in Scottsdale, Arizona. I’m Keith Stewart. I’m one of the organizers of the meeting and currently working in Toronto Canada. I’m joined by Professor Gareth Morgan, our core organizer with me from New York University Langone Cancer Center and Dr. Faith Davis, who has also been chairing one of the sessions today and presented.Keith Stewart:So, we’re going to…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | Join experts @FaithEDavies1, @DrGarethMorgan1 & @akeithstewart as they share their highlights from #Myeloma22, including MRD, antibody treatment for amyloidosis, and more: 👉https://t.co/kPqlHwhLY2👈 #MMsm #Myeloma #HemOnc https://t.co/MpOqEUzJro
-
-
Mashup Score: 2
Lawrence Boise:Hello, I’m Lawrence Boise from the Winship Cancer Institute at Emory University. And along with my co-chair, Dr Paola Neri from the University of Calgary. We are at the Myeloma 2022 in Scottsdale, Arizona. And we just finished up with a really exciting session on novel targets in myeloma.Lawrence Boise:Paula, when… I love novel target sessions, because there’s a lot of variety…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | Paola Neri (@UCalgary) and Lawrence Boise (@WinshipAtEmory) have a fascinating discussion on novel targets in myeloma, including RAS, PIKfyve & resistance to PIs and IMiDs. Watch here: 👉https://t.co/bGtb0p5gXb👈 #MMsm #Myeloma22 #HemOnc #ImmunoOnc https://t.co/JF4iL5qvr6
-
-
Mashup Score: 0Myeloma Sessions: Day 2 highlights from Myeloma 2022 | VJHemOnc - 2 year(s) ago
Irene Ghobrial:My name is Irene Ghobrial. I’m from the Dana-Farber Cancer Institute in Boston, Massachusetts.Sigurdur Kristinsson:My name is Sigurdur Kristinsson. I’m from the University of Iceland. So the iStopMM study is called Iceland screens and treats and prevents myeloma. So basically we wanted to ask, “Should we screen for MGUS? Does that lead to an improvement in overall survival? So…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | We're pleased to bring you our latest session from #Myeloma22. @DrGarethMorgan1, @Rfonsi1, @Leif_Bergsagel & @akeithstewart have a fascinating discussion on highlights from this year's meeting. Watch here: 👉https://t.co/AmdhbjngyK👈 #MMsm https://t.co/vFIewp0AhU
-
-
Mashup Score: 1Myeloma Sessions: Genomics in the age of I-O | VJHemOnc - 2 year(s) ago
Gareth Morgan:Hello, my name is Gareth Morgan. I’m here in Scottsdale, Arizona at the Myeloma 2022 meeting. I’m with two good colleagues, Leo Rasche, and Francesco Maura. We’ve just been in the genomics session. I’d just like to ask you, Leo, what did you think of the session and what did you think the take home message was?Leo Rasche:Oh, the session was great. But it’s difficult to have a good…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | @DrGarethMorgan1, Leo Rasche (@Uni_WUE) & @FrancescoMaura4 have a fascinating discussion on genomics in the age of immunotherapy at #Myeloma22. Watch now: 🎥: https://t.co/cPdRbVjkxM #MMsm #HemOnc #Myeloma #ImmunoOnc https://t.co/kDi1i1URuw
-
-
Mashup Score: 0
Hermann Einsele:Hello, everybody. My name is Hermann Einsele. I am based in Würzburg in Germany, and it’s my great pleasure to report from the Myeloma 2022 in Scottsdale. And it’s a great pleasure for me for the discussion to have two real experts with me on T-cell engaging therapies in myeloma, Professor Nina Shah and Professor Tom Martin from California. And the topic of our discussion today…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Want to learn about the latest in T-cell engager therapies in myeloma? Leading experts @ninashah33, @H_Einsele, and @TomBmt133 discuss the challenges & opportunities of T-cell engagers at #Myeloma22: 👉https://t.co/VcLq7u26q4👈 #VJSessions #MMsm #Myeloma https://t.co/IW1E2dwOcw
-
-
Mashup Score: 1Myeloma 2022 | VJHemOnc - 2 year(s) ago
VJHemOnc was pleased to be the official media partner for Myeloma 2022, the 15th workshop exploring myeloma biology and innovation. The workshop featured a global expert faculty discussing the latest updates in multiple myeloma. This year’s key topics included the clinical management of myeloma, defining the molecular basis of myeloma in the development of novel targets, immune-based therapies,…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VJHemOnc is pleased to bring you all the latest updates in myeloma from #Myeloma22, featuring detailed presentations from leading experts in the field. Watch here: 👉https://t.co/5wnmV5tK3u👈 #MMsm #Myeloma https://t.co/d2WA42GKjh
-
-
Mashup Score: 2Myeloma Sessions: Novel targets in 2022 | VJHemOnc - 2 year(s) ago
Faith Davies:Thank you for joining us. We’re currently at Myeloma 2022, and it’s a real pleasure for me to introduce two of my colleagues. We have Charlotte Pawlyn, who is from the Institute of cancer research in the Royal Marsden hospital in London. And we have Hearn Cho, who is from the Mount Sinai hospital in New York, and is also the chief medical officer for the MMRF. And as you can see, two…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | Want to hear more about novel targets in myeloma? Join @FaithEDavies1, @HJChoMDPhD1 & @_DrCP as they discuss IMiD resistance, novel treatments for amyloidosis, and more. 👉https://t.co/M9dFEWkyEk👈 #MMsm #HemOnc #Myeloma #ImmunoOnc #Myeloma22 https://t.co/0EG1rxdckX
-
-
Mashup Score: 1Myeloma Sessions: Day 2 highlights from Myeloma 2022 | VJHemOnc - 2 year(s) ago
Irene Ghobrial:My name is Irene Ghobrial. I’m from the Dana-Farber Cancer Institute in Boston, Massachusetts.Sigurdur Kristinsson:My name is Sigurdur Kristinsson. I’m from the University of Iceland. So the iStopMM study is called Iceland screens and treats and prevents myeloma. So basically we wanted to ask, “Should we screen for MGUS? Does that lead to an improvement in overall survival? So…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | @DrGarethMorgan1, @Rfonsi1, @Leif_Bergsagel & @akeithstewart discuss the biology behind BCL2 inhibitors, resistance to immunotherapies, and more at #Myeloma22. Watch now: 👉https://t.co/HZHAFkRIv3👈 #MMsm https://t.co/vQHBofBXbO
-
At #Myeloma22, leading experts got together to bring you the latest in myeloma treatment & management. @IreneGhobrial, Yael Cohen, @Dr_Rodg & @EileenMBoyle talk on understanding myeloma at the single-cell level: 👉https://t.co/3Ay2Tm2b26👈 #MMsm #HemOnc #Myeloma #ImmunoOnc https://t.co/eH2lJ02CJC